Aurinia Sets February 26 Date to Report 2025 Results and Business Update
Aurinia Pharmaceuticals announced it will report its financial results for the three and twelve months ended December 31, 2025, and provide a business update on February 26, 2026. This update will offer insights into the progress of its flagship lupus nephritis drug LUPKYNIS and investigational autoimmune therapy aritinercept, and their impact on the company's growth trajectory. An analyst from TipRanks' AI Analyst, Spark, rates AUPH as "Outperform," citing strong financial performance and promising clinical developments.
Aurinia Pharmaceuticals Inc (AUPH) has announced that it will release its financial results for the fourth quarter and full year ended December 31, 2025, on February 26, 2026.
Aurinia Pharmaceuticals Inc (AUPH) is scheduled to release its financial results for the fourth quarter and full year 2025 on February 26, 2026. The company's management will provide a detailed interpretation of the financial report, discuss recent business developments, and outline strategic progress. This event aims to offer investors and market observers a comprehensive understanding of Aurinia's financial status and operational performance.
Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced it will report its financial results for the three and twelve months ending December 31, 2025, and provide a business update on February 26, 2026. The company's management team will host a webcast and conference call at 8:30 a.m. ET on that date. Aurinia specializes in biopharmaceuticals for autoimmune diseases, including LUPKYNIS® for lupus nephritis and aritinercept in development.
The Technical Signals Behind (AUPH) That Institutions Follow
This article provides a technical analysis of Aurinia Pharmaceuticals Inc (NASDAQ: AUPH), highlighting divergent sentiment across different time horizons. It outlines institutional trading strategies based on AI models, including position trading, momentum breakout, and risk hedging strategies, with specific entry, target, and stop-loss zones. The analysis also details support and resistance levels for near-term, mid-term, and long-term outlooks for AUPH.
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Receives Consensus Rating of "Hold" from Analysts
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has received a consensus "Hold" rating from analysts, with an average one-year price target of $17.25 based on reports from six analysts. While Jefferies upgraded AUPH to a "Buy" with a $21 price target, other firms generally maintained or lowered their ratings. The company's stock is trading near $14.23, with strong liquidity and institutional ownership.
83,780 Shares in Aurinia Pharmaceuticals Inc $AUPH Purchased by Navellier & Associates Inc.
Navellier & Associates Inc. recently acquired 83,780 shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) valued at approximately $926,000, establishing a 0.06% stake in the company. Institutional investors collectively own 36.83% of Aurinia Pharmaceuticals. The stock currently holds a consensus "Hold" rating from analysts with an average price target of $17.25, while trading with a market cap of $1.92 billion and a P/E ratio of 26.00.
Aurinia Pharmaceuticals Inc (AUPH): Investor Outlook and Analyst Consensus Reveal Promising 14.71% Upside
Aurinia Pharmaceuticals Inc. (AUPH) shows promising investor outlook and analyst consensus, with a potential upside of 14.71%. The company, a key player in biotechnology, focuses on autoimmune diseases and is supported by its flagship product, LUPKYNIS, and strategic collaborations with Otsuka Pharmaceutical. Strong financial health, efficient management, and optimistic analyst ratings position AUPH as an attractive growth prospect in the biotech sector.
Precision Trading with Aurinia Pharmaceuticals Inc (AUPH) Risk Zones
This article provides a precision trading analysis for Aurinia Pharmaceuticals Inc (AUPH), indicating a neutral near and mid-term outlook but a positive long-term bias. It highlights an exceptional risk-reward setup targeting a 12.4% gain with minimal risk and outlines three distinct institutional trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, based on AI-generated signals for various time horizons.
Hussman Strategic Advisors Inc. Cuts Position in Aurinia Pharmaceuticals Inc $AUPH
Hussman Strategic Advisors Inc. significantly decreased its stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) by 64.7% in Q3, selling 231,000 shares. Despite this reduction, Aurinia Pharmaceuticals reportedly beat Q3 earnings and revenue expectations, and the stock maintains an average analyst "Hold" rating with an average target price of $17.25. Other institutional investors like Vanguard and Nordea increased their positions, while some analysts upgraded their ratings and price targets for the biotechnology company.
Technical Reactions to AUPH Trends in Macro Strategies
This article analyzes Aurinia Pharmaceuticals Inc (AUPH) using AI models, highlighting "divergent sentiment" across time horizons. It provides specific trading strategies—Position, Momentum Breakout, and Risk Hedging—with entry zones, targets, and stop losses. The analysis suggests choppy conditions for AUPH and offers multi-timeframe signal analysis and real-time access to detailed trading insights.
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Receives Average Recommendation of "Hold" from Analysts
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has received an average "Hold" recommendation from seven research firms, with an average 1-year price target of $17.25. While some analysts upgraded the stock or raised price targets, others lowered ratings. The company recently reported strong Q3 2025 earnings, beating estimates for both EPS and revenue.
Implied Volatility Surging for Aurinia Pharmaceuticals Stock Options
Implied volatility for Aurinia Pharmaceuticals (AUPH) stock options is surging, particularly for the July 18, 2025 $2.00 Call, indicating that the market anticipates a significant price movement. This rise in implied volatility, combined with analysts increasing their earnings estimates for the company, suggests a potential trading opportunity for options traders, possibly through selling premium. Zacks analysts currently rate Aurinia Pharmaceuticals as a #3 (Hold) and have raised current quarter earnings estimates from 10 cents to 18 cents per share.
Aurinia downgraded at RBC on risk-reward setup
RBC Capital has downgraded Aurinia Pharmaceuticals to Sector Perform from Outperform, revising its price target to $10 from $13. The adjustment is primarily due to a less favorable risk-reward outlook after the recent positive news regarding Lupkynis and the anticipated growth slowing down.
How Investors May Respond To Aurinia Pharmaceuticals (AUPH) Expanding Autoimmune Pipeline And Deepening Otsuka Collaboration
Aurinia Pharmaceuticals is expanding its autoimmune pipeline with candidate AUR200 and deepening its collaboration with Otsuka Pharmaceutical to enhance global reach for LUPKYNIS. While LUPKYNIS remains the primary revenue driver, these diversification efforts aim to reduce concentration risk and influence investor perception of the company's long-term growth potential and stability. The article discusses how these developments, including upcoming data presentations, could reshape Aurinia's investment narrative and impact its fair value.
Trading the Move, Not the Narrative: (AUPH) Edition
This article provides an AI-generated analysis for Aurinia Pharmaceuticals Inc (NASDAQ: AUPH), highlighting weak near and mid-term sentiment but a strong long-term outlook. It details specific trading strategies, including long, breakout, and short positions, along with support and resistance levels across different timeframes. The analysis also emphasizes an exceptional risk-reward short setup for the stock.
Aurinia Pharmaceuticals (NASDAQ:AUPH) Share Price Passes Above 50-Day Moving Average - Here's Why
Aurinia Pharmaceuticals (NASDAQ:AUPH) saw its share price briefly rise above its 50-day moving average of $15.56, reaching $15.61 on Friday. Despite trading at $15.15 with over 1.2 million shares changing hands, the company holds a "Hold" rating from analysts with an average price target of $17.25. Aurinia recently exceeded earnings estimates, reporting $0.23 EPS against an expected $0.16 and revenue of $73.47 million, surpassing analyst forecasts of $67.70 million.
Aurinia Pharmaceuticals Inc - Common Shares (NQ: AUPH)
This page provides recent news headlines and financial data for Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH). It lists several press releases from May and April 2021, detailing clinical study results, financial reports, investor conference participation, and patient access initiatives related to their LUPKYNIS™ (voclosporin) product. The current stock price and performance are also displayed.
(AUPH) Volatility Zones as Tactical Triggers
This article analyzes Aurinia Pharmaceuticals Inc (AUPH) using AI models to identify volatility zones and tactical triggers for trading. It outlines three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, emphasizing a strong risk-reward setup. The analysis also includes multi-timeframe signal analysis, showing weak near-term sentiment but strong long-term prospects.
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Is a Favorite Amongst Institutional Investors Who Own 54%
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) shows significant institutional ownership, with 54% of its shares held by institutions. This concentration of ownership can make the stock price sensitive to institutional trading actions. Additionally, the company has 43% ownership by the general public, and insiders hold a meaningful stake of US$39 million, indicating strong alignment with shareholder interests.
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Given Consensus Recommendation of "Hold" by Brokerages
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) has received a "Hold" consensus recommendation from seven research firms, with an average 1-year target price of $17.25. The company recently surpassed earnings and revenue estimates, reporting $0.23 EPS and $73.47 million in revenue. Institutional investors hold approximately 36.83% of the stock, and its current market capitalization stands at $2.14 billion.
Aurinia Pharmaceuticals (NASDAQ:AUPH) rises 3.1% this week, taking three-year gains to 292%
Aurinia Pharmaceuticals (NASDAQ:AUPH) experienced a 3.1% rise this week, contributing to a substantial 292% gain over the past three years for its shareholders. The company transitioned from a loss to profitability during this period, which likely fueled the strong share price increase. Over the last twelve months, Aurinia Pharmaceuticals delivered an 81% total shareholder return, indicating recent positive sentiment.
Aurinia Pharmaceuticals (NASDAQ:AUPH) rises 3.1% this week, taking three-year gains to 292%
Aurinia Pharmaceuticals (NASDAQ:AUPH) has seen its share price increase by 292% over the last three years, including a 3.1% rise this past week and a 27% gain in the last three months. This significant growth is attributed to the company transitioning from a loss to profitability. The company has also delivered an 81% total shareholder return in the last twelve months, indicating positive sentiment.
Aurinia Pharmaceuticals (NASDAQ:AUPH) rises 3.1% this week, taking three-year gains to 292%
Aurinia Pharmaceuticals (NASDAQ:AUPH) saw its share price increase by 3.1% this week, contributing to a substantial 292% gain over the past three years. This strong performance is linked to the company's successful transition from a loss-making entity to profitability. The article highlights that recent positive sentiment is also reflected in an 81% total shareholder return over the last twelve months.
Aurinia Pharmaceuticals stock hits 52-week high at 16.49 USD By Investing.com
Aurinia Pharmaceuticals Inc. (AUPH) reached a new 52-week high of $16.49 USD, marking an 83.69% increase over the past year, driven by strong fundamentals like $265.8M revenue and an 80.2% gross profit margin. Despite varying analyst ratings on its lupus nephritis treatment, Lupkynis, the company's financial health is rated "GREAT" by InvestingPro, indicating undervaluation and predicted continued profitability. This strong performance and positive market sentiment underscore investor confidence in Aurinia's future potential.
Aurinia Pharmaceuticals stock hits 52-week high at 16.49 USD By Investing.com
Aurinia Pharmaceuticals Inc. (AUPH) reached a 52-week high of $16.49 USD, marking an 83.69% increase over the past year, driven by strong fundamentals like $265.8M revenue with 20.6% growth and an 80.2% gross profit margin. Despite some analyst downgrades for its lupus nephritis treatment Lupkynis, the company maintains a "GREAT" financial health rating and analysts predict continued profitability.
Marex Group plc Buys Shares of 135,000 Aurinia Pharmaceuticals Inc $AUPH
Marex Group plc acquired 135,000 shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) in the second quarter, valued at approximately $1.143 million, increasing their stake to 0.10%. Other institutional investors also significantly increased their positions, contributing to institutional ownership of about 36.83%. Aurinia Pharmaceuticals reported strong financial results, surpassing analyst expectations for EPS and revenue, though the stock currently holds an average "Hold" rating with a target price of $17.25.
Aruinia discloses FDA information request on Lupkynis amid top regulator’s exit
Aruinia Pharmaceuticals disclosed that the FDA has requested additional information regarding its drug Lupkynis, intended for treating lupus nephritis. This request comes shortly after the departure of the company's chief regulatory officer. The company noted that the FDA's query aligns with typical practice for post-marketing requirements.
Armistice Capital LLC Sells 3,370,400 Shares of Aurinia Pharmaceuticals Inc $AUPH
Armistice Capital LLC significantly reduced its stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) by selling 3,370,400 shares, representing a 67.4% decrease in its holdings. Following the sale, Armistice Capital now owns 1,629,600 shares, valued at approximately $13.8 million. The article also notes that Aurinia Pharmaceuticals recently surpassed earnings and revenue estimates, and analyst sentiment is mixed despite a recent upgrade from Jefferies to "Buy."
Aurinia Pharmaceuticals Inc $AUPH Shares Purchased by Jump Financial LLC
Jump Financial LLC significantly increased its stake in Aurinia Pharmaceuticals (NASDAQ:AUPH) by 669.1% in Q2, bringing their total to 390,101 shares, representing approximately 0.30% of the company. Institutional investors now collectively own about 36.83% of the stock. Analyst ratings for Aurinia are mixed with a consensus "Hold" and an average price target of $17.25, while the company recently exceeded Q3 earnings and revenue estimates.
State Board of Administration of Florida Retirement System Has $1.22 Million Stock Position in Aurinia Pharmaceuticals Inc $AUPH
The State Board of Administration of Florida Retirement System significantly increased its stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) by 240.9%, now owning 143,885 shares valued at $1.22 million. Aurinia Pharmaceuticals recently reported an earnings beat with $0.23 EPS against an expected $0.16 and revenue of $73.47 million, exceeding analyst estimates. While some analysts have upgraded the stock, the consensus remains a "Hold" rating with an average target price of $17.25.
Schroder Investment Management Group Has $4.64 Million Holdings in Aurinia Pharmaceuticals Inc $AUPH
Schroder Investment Management Group significantly increased its stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) by 74% in Q2, bringing its total holdings to 547,802 shares valued at $4.64 million. This move comes as Aurinia Pharmaceuticals reported strong quarterly earnings, surpassing analyst estimates, and despite mixed analyst ratings with a consensus "Hold" but some recent upgrades to "Buy." The article details other institutional investments and the company's recent financial performance.
Virtus Investment Advisers LLC Has $457,000 Stake in Aurinia Pharmaceuticals Inc $AUPH
Virtus Investment Advisers LLC significantly increased its stake in Aurinia Pharmaceuticals Inc, boosting its holdings by 45.7% to 53,997 shares, valued at approximately $457,000. This increase follows strong quarterly results where Aurinia Pharmaceuticals exceeded earnings and revenue expectations. Despite mixed analyst sentiment, with a consensus "Hold" rating, the company's financial performance and institutional investment activity suggest ongoing interest in its stock.
Leerink Partners Downgrades Aurinia Pharmaceuticals to Market Perform From Outperform, Adjusts PT to $16 From $15
Leerink Partners has downgraded Aurinia Pharmaceuticals to Market Perform from Outperform, simultaneously adjusting its price target to $16 from $15. This adjustment follows earlier news of Aurinia Pharmaceuticals shares falling after Leerink Partners' downgrade and recent updates in analyst ratings from other financial firms. Aurinia Pharmaceuticals is a biopharmaceutical company focused on autoimmune diseases, with its primary asset being LUPKYNIS (voclosporin) for lupus nephritis.
Aurinia Pharmaceuticals Inc $AUPH Stake Trimmed by Geode Capital Management LLC
Geode Capital Management LLC reduced its stake in Aurinia Pharmaceuticals (NASDAQ:AUPH) by 9.1% in Q2, selling 157,240 shares and retaining 1,577,060 shares valued at approximately $13.36 million. The company reported strong Q3 earnings, beating analyst expectations with an EPS of $0.23 and revenue of $73.47 million. Analyst ratings for AUPH are mixed, with a consensus "Hold" rating and a target price of $17.67, despite a recent upgrade from Jefferies to "Buy" with a $21 price target.
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Receives Consensus Rating of "Hold" from Analysts
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has received a consensus "Hold" rating from analysts, with specific firms like Jefferies upgrading to "Buy" while Bloom Burton downgraded to "Hold". The company recently reported strong quarterly earnings, beating analyst estimates for both EPS and revenue. Aurina's stock is currently trading around $16.17, reflecting a market capitalization of approximately $2.13 billion.
Advantage Alpha Capital Partners LP Takes $204,000 Position in Aurinia Pharmaceuticals Inc $AUPH
Advantage Alpha Capital Partners LP has acquired a new position of 24,079 shares, valued at approximately $204,000, in Aurinia Pharmaceuticals Inc. Several other institutional investors also increased or initiated stakes in the biotechnology company, bringing institutional ownership to 36.83%. Aurinia Pharmaceuticals beat its quarterly earnings expectations and faces mixed analyst sentiment, with a consensus "Hold" rating and an average price target of $17.67.
Segall Bryant & Hamill LLC Sells 221,933 Shares of Aurinia Pharmaceuticals Inc $AUPH
Segall Bryant & Hamill LLC reduced its stake in Aurinia Pharmaceuticals (NASDAQ:AUPH) by 60.2% in the second quarter, selling 221,933 shares and retaining 146,854 shares valued at $1.244 million. Despite this, Aurinia Pharmaceuticals reported strong quarterly earnings, surpassing analyst estimates with EPS of $0.23 and revenue of $73.47 million, and is trading near its 52-week high. Analysts remain mixed on the stock, with a consensus "Hold" rating and an average target price of $17.67.
Improved Revenues Required Before Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Stock's 27% Jump Looks Justified
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) recently saw a 27% share price jump, bringing its annual gain to 76%. However, its current price-to-sales (P/S) ratio of 7.2x is below the biotech industry average, suggesting that its revenue growth is not keeping pace. Analysts project a 16% annual revenue growth for Aurinia over the next three years, significantly lower than the industry forecast of 122%, which explains the company's lower P/S ratio and indicates potential challenges for future share price appreciation without improved revenue performance.
Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025
Aurinia Pharmaceuticals Inc. announced it will report financial results for the three and nine months ended September 30, 2025, and provide a business update on November 4, 2025. The company will host a webcast and conference call at 8:30 a.m. ET on this date. Aurinia is a biopharmaceutical company focused on autoimmune diseases, known for its FDA-approved therapy LUPKYNIS® (voclosporin) for lupus nephritis and developing aritinercept.
Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress
Aurinia Pharmaceuticals Inc. announced strong financial results for the Q3 and first nine months of 2025, driven by significant growth in LUPKYNIS sales, which increased 27% and 24% respectively compared to the previous year. The company also raised its full-year 2025 total revenue guidance to $275 to $280 million and net product sales guidance to $265 to $270 million. Additionally, Aurinia provided an update on its pipeline, with aritinercept advancing towards clinical studies for two autoimmune diseases.
Aurinia Pharmaceuticals Inc. SEC 10-Q Report
Aurinia Pharmaceuticals Inc. has released its Q3 2025 10-Q report, showcasing significant financial growth driven by increased market penetration of its flagship product, LUPKYNIS. The company reported substantial increases in total revenue and net income, alongside operational advancements including regulatory approvals for LUPKYNIS in new international markets and plans for new product development. Aurinia also highlighted the commencement of manufacturing at its new facility to enhance production efficiency.
FDA Turmoil Spills Over To Aurinia Pharma As Lawsuit Targets Ex-Drug Review Chief — Retail Traders Cry ‘Stock Manipulation’
The FDA's drug evaluation agency is facing turmoil after its acting director resigned, alleging political interference in drug approvals. This development closely follows a lawsuit filed by Aurinia Pharma against the ex-director, George Tidmarsh, who had criticized their kidney inflammation drug, Lupkynis. Retail traders have expressed concerns about potential stock manipulation in connection with Tidmarsh's actions and the subsequent events.
Aurinia Pharmaceuticals: Lupkynis Growth And AUR200 Pipeline Justify Buy Rating
Aurinia Pharmaceuticals (AUPH) is given a 'BUY' rating due to strong sales growth of its lupus nephritis drug, Lupkynis, and a solid cash position that supports pipeline development. Lupkynis is the first FDA-approved oral therapy for lupus nephritis, showing 22% year-over-year revenue growth. The company's pipeline includes AUR200, an investigational drug targeting dual immune proteins, offering future diversification in the autoimmune market.
Aurinia Pharmaceuticals Experiences Revision in Score Amid Strong Financial Metrics and Market Position - Markets Mojo
Aurinia Pharmaceuticals has undergone a valuation adjustment, reflecting strong financial metrics including a high return on capital employed and a favorable P/E ratio compared to peers. The company's performance has outpaced the S&P 500 over the past year, demonstrating its competitive strength in the Pharmaceuticals & Biotechnology sector despite recent stock price fluctuations. Key financial figures like P/E of 19, ROCE of 99.51%, and a PEG ratio of 0.10 underscore its robust profile.
Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025 - BioSpace
Aurinia Pharmaceuticals Inc. announced five upcoming poster presentations of new data on LUPKYNIS® (voclosporin) at two major medical conferences in late 2025: the American College of Rheumatology (ACR) Convergence and the American Society of Nephrology (ASN) Kidney Week. These presentations, often in collaboration with independent investigators, will cover real-world effectiveness, usage in pediatric patients, and mechanistic data regarding voclosporin's disposition and distribution. The company highlights its commitment to advancing lupus nephritis care by deepening the medical community's understanding of voclosporin's role in clinical practice.
Aurinia to present new Lupkynis® data at ACR Convergence and ASN Kidney Week 2025 - MarketScreener
Aurinia Pharmaceuticals Inc. is set to present new data on its drug Lupkynis® at the American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025. This announcement highlights the company's ongoing commitment to developing therapies for autoimmune diseases, particularly lupus nephritis. The company recently increased its revenue guidance for full year 2025, following strong Q2 earnings.
Aurinia to Present New LUPKYNIS® Data at ACR Convergence and ASN Kidney Week 2025 - TradingView
Aurinia Pharmaceuticals Inc. (AUPH) announced that new data on its drug LUPKYNIS® will be presented at two major medical conferences in 2025: American College of Rheumatology Convergence and American Society of Nephrology Kidney Week. This indicates ongoing research and dissemination of findings related to their key product.
Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025 - Zenopa
Aurinia Pharmaceuticals Inc. announced five poster presentations of new LUPKYNIS® (voclosporin) data at upcoming American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025 conferences. These presentations, in collaboration with independent investigators, will cover real-world effectiveness, usage in pediatric patients, voclosporin disposition and clearance, and use in combination with other therapies for lupus nephritis. Dr. Greg Keenan, CMO of Aurinia, emphasized that these findings will enhance the medical community's understanding of voclosporin's role in clinical practice.
Aurinia to present new voclosporin data at rheumatology conferences By Investing.com - Investing.com Canada
The article indicates that there was an application error while loading the Investing.com page for the news about Aurinia presenting new voclosporin data at rheumatology conferences. As a result, the content of the article is unavailable. The issue appears to be a client-side exception.
Aurinia Pharmaceuticals Inc. Announces Upcoming Presentations of New Data on LUPKYNIS®? at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025 - MarketScreener
Aurinia Pharmaceuticals Inc. announced upcoming presentations of new data on LUPKYNIS (voclosporin) at two major medical conferences in October and November 2025. Five posters, developed in collaboration with independent investigators, will highlight real-world effectiveness, usage, and disposition of LUPKYNIS in lupus nephritis patients. LUPKYNIS is an FDA-approved oral therapy for active lupus nephritis.
